ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2213

The Four Stages of Fibromyalgia: Potential for More Precise Treatment Approaches

Mark Gostine1, Fred Davis1, Bradley Roberts2, Rebecca Risko2, Joseph C Cappelleri3, Andrew Clair4 and Alesia Sadosky5, 1Michigan Pain Consultants, PC, Grand Rapids, MI, 2ProCare Systems, Inc., Grand Rapids, MI, 3Statistics, Pfizer Inc, New London, CT, 4Pfizer, New York, NY, 5Pfizer Inc,, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Chronic pain, Clinical practice, Co-morbidities, Fibromyalgia and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and tenderness making it difficult to manage. Accounting for FM heterogeneity might elicit an improvement in patient treatment. Chronic diseases are a dynamic process with increasing and decreasing symptomology and clinical manifestations. Several diseases similar to FM have known chronicity trends; rheumatoid arthritis has stages indicated by disease progression, and according to the Centers for Disease Control and Prevention, three different disease courses exist. The objective of this study was to cluster patients into stages, or similar disease profiles, based on severity of FM (i.e., patient co-morbidities, regions of pain, and procedures), as well as time.

Methods: We identified 2,529 FM patients with a total of 79,570 clinical visits between January 1999 and February 2014 from an administrative claims data. Patients were clustered based on similarity of co-morbidities (symptom severity), region of pain (widespread pain), and procedures (treatment intensity) by implementing a sequence of unsupervised and supervised learning techniques. Text analysis and a review of physician notes were conducted to obtain secondary conditions and diseases to assist in the understanding of stage classification.

Results: There were four parent stages of FM identified and labeled: 1) regional FM with classic symptoms; 2) generalized FM with increasing widespread pain and some additional symptoms; 3) FM with advanced and associated conditions, increasing widespread pain, increased sleep disturbances, and chemical sensitivity; and 4) secondary FM reactive to disease. Approximately 45% of patient observations were reclassified when the constraints of time were lifted. Most notably, the rate of stage misclassification dramatically reduced from 11.2% to 4.4% when patients were reclassified based on exponential increases in disease severity as opposed to time. These findings lend support that FM stages are more characterized by disease severity and are less time-dependent.

Conclusion: Generally, patients increase in their symptom severity and region of pain by stage. Parallels are beginning to emerge between the different stages and presentations of underlying conditions. General clustering seems to be occurring but requires more research. Nonetheless, this work makes a case for the presence of FM stages in which important clinical ramifications exist that may lead to a more precise treatment approach for FM patients.


Disclosure: M. Gostine, None; F. Davis, None; B. Roberts, None; R. Risko, None; J. C. Cappelleri, None, 3; A. Clair, Pfizer Inc, 1,Pfizer Inc, 3; A. Sadosky, None, 3.

To cite this abstract in AMA style:

Gostine M, Davis F, Roberts B, Risko R, Cappelleri JC, Clair A, Sadosky A. The Four Stages of Fibromyalgia: Potential for More Precise Treatment Approaches [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-four-stages-of-fibromyalgia-potential-for-more-precise-treatment-approaches/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-four-stages-of-fibromyalgia-potential-for-more-precise-treatment-approaches/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology